Epidermolysis Bullosa Acquisita Latest Advances

Find the Latest Research About Epidermolysis Bullosa Acquisita

Last Updated: 04/28/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 848 publications

The role of antibody class and target on subepidermal blistering disease phenotype and management.

The role of antibody class and target on subepidermal blistering disease phenotype and management.

Journal: Italian journal of dermatology and venereology
Published: March 16, 2026

Cryptococcus neoformans Meningitis in a Patient With Epidermolysis Bullosa and Rheumatoid Arthritis.

Cryptococcus neoformans Meningitis in a Patient With Epidermolysis Bullosa and Rheumatoid Arthritis.

Journal: Cureus
Published: February 13, 2026

Selective Complement Inhibition in Anti-p200 Pemphigoid: Immune Infiltrate Profiles and Therapeutic Implications Compared to Bullous Pemphigoid.

Selective Complement Inhibition in Anti-p200 Pemphigoid: Immune Infiltrate Profiles and Therapeutic Implications Compared to Bullous Pemphigoid.

Journal: Biomolecules
Published: January 06, 2026

The Changing Trends in the Incidence and Clinical Presentation of Immunobullous Disorders Before and During the COVID-19 Era in a Tertiary Healthcare Centre in Andhra Pradesh.

The Changing Trends in the Incidence and Clinical Presentation of Immunobullous Disorders Before and During the COVID-19 Era in a Tertiary Healthcare Centre in Andhra Pradesh.

Journal: Cureus
Published: December 01, 2025

Immunomodulators and Antineoplastics Are Reported in Drug-Associated Epidermolysis Bullosa Acquisita Flares: A Retrospective Analysis of 58 Reported Cases Utilizing Multiple International Pharmacovigilance Databases.

Immunomodulators and Antineoplastics Are Reported in Drug-Associated Epidermolysis Bullosa Acquisita Flares: A Retrospective Analysis of 58 Reported Cases Utilizing Multiple International Pharmacovigilance Databases.

Journal: International journal of dermatology
Published: October 23, 2025

Case report: Epidermolysis bullosa acquisita following dipeptidyl peptidase-4 inhibitor therapy and complicated by immune thrombocytopenic purpura.

Case report: Epidermolysis bullosa acquisita following dipeptidyl peptidase-4 inhibitor therapy and complicated by immune thrombocytopenic purpura.

Journal: Frontiers in immunology
Published: October 13, 2025

Type VII Collagen Disorders Simplified.

Type VII Collagen Disorders Simplified.

Journal: Cutis
Published: October 07, 2025

Epidermolysis Bullosa Acquisita With Extensive Esophageal Erosions.

Epidermolysis Bullosa Acquisita With Extensive Esophageal Erosions.

Journal: The Journal of dermatology
Published: September 23, 2025

Lyme Disease Causing Complex Bullous Lesions: A Case Report.

Lyme Disease Causing Complex Bullous Lesions: A Case Report.

Journal: Cureus
Published: September 21, 2025

The Retinoid Tamibarotene Aggravates Skin Inflammation in a Model of Bullous Pemphigoid-like Epidermolysis Bullosa Acquisita.

The Retinoid Tamibarotene Aggravates Skin Inflammation in a Model of Bullous Pemphigoid-like Epidermolysis Bullosa Acquisita.

Journal: Cells
Published: September 05, 2025

Spectrum mining of immune checkpoint inhibitor-related cutaneous toxicities and analysis of associated factors based on FAERS.

Spectrum mining of immune checkpoint inhibitor-related cutaneous toxicities and analysis of associated factors based on FAERS.

Journal: Frontiers in pharmacology
Published: August 12, 2025

Recalcitrant epidermolysis bullosa acquisita treated with upadacitinib as a bridge to rituximab.

Recalcitrant epidermolysis bullosa acquisita treated with upadacitinib as a bridge to rituximab.

Journal: JAAD case reports
Published: August 11, 2025
Showing 1-12 of 848

Last Updated: 04/28/2026